Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov110910.25208/vdv1109DRUG TREATMENT IN DERMATOVENEROLOGYФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИResearch ArticleThe Actual Challenges of Biologics Treatment in Patients with PsoriasisСовременные проблемы генно-инженерной биологической терапии больных псориазомhttps://orcid.org/0000-0002-1450-4942151120-0018386708-7386BakulevAndrey L.БакулевАндрей Леонидович
Russian Federation

Dr. Sci. (Medicine), Prof., Department of Dermatovenereology and Cosmetology

д.м.н., профессор, заведующий кафедрой дерматовенерологии и косметологии

info@sarderma.ruSaratov State Medical University of the Ministry of Healthcare of the Russian FederationФГБОУ ВО Саратовский ГМУ им. В.И.Разумовского Минздрава России0208202096251572403202002042020Copyright ©; 2020, Bakulev A.L.Copyright ©; 2020, Бакулев А.Л.2020Bakulev A.L.Бакулев А.Л.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1109

The article contain the main challenges meet doctors in real practice using biologics for treatment patients with psoriasis.Different aspects and concerns have been analised from new point of view: the aims of Bx therapy (incl. control of remission, personalized goals, etc.) primary and secondary responses, immunogenicity, treatment survival, retention rate or long lasting regain of response in psoriasis patients treated by biologics.

В статье приводится обзор литературы по актуальным проблемам применения генно-инженерных биологических препаратов (ГИБП) в лечении больных псориазом.

С современных позиций анализируются различные аспекты и проблемы применения ГИБП — цель терапии (PASI, BSA, контролируемая ремиссия, индивидуальная цель), возможности ее достижения с использованием ГИБП; понятия первичных и вторичных неответчиков на лечение ГИБП; вопросы иммуногенности и факторы, влияющие на данный феномен; ускользание терапевтического ответа и его флюктуация в процессе долгосрочного применения ГИБП у больных псориазом.

psoriasistreatmentbiologics productstreatment goalimmunogenicityefficacylost of efficacyretention rate of responseпсориазлечениегенно-инженерные биологические препаратыцель терапиииммуногенностьэффективностьускользание терапевтического ответафлюктуация терапевтического ответаElmets C.A., Lim H.W., Stoff B., Connor C., Cordoro K.M., Lebwohl M., Armstrong A.W., Davis DMR, Elewski B.E., Gelfand J.M., Gordon K.B., Gottlieb A.B., Kaplan D.H., Kavanaugh A., Kiselica M., Kivelevitch D., Korman N.J., Kroshinsky D., Leonardi C.L., Lichten J., Mehta N.N., Paller A.S., Parra S.L., Pathy A.L., Farley Prater E.A., Rupani R.N., Siegel M., Strober B.E., Wong E.B., Wu J.J., Hariharan V., Menter A. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep; 81 (3): 775—804.Kogan N., Raimondo N., Gusis S.E., Izcovich A., Abarca Duran J.A., Barahona-Torres L., Blanco O., Quintana G.B., Briones M.C., Castro C., Castro Vargas E.G., Criniti J., Diez de Medina J.C., Franco M., Gómez M., Levrero V.P., Martínez López J.E., Valenzuela F. Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO — Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society). Int J Dermatol. 2019 Aug; 58 Suppl 1: 4—28.American Academy of Dermatology Work Group, Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., Gottlieb A., Koo J.Y., Lebwohl M., Leonardi C.L., Lim H.W., Van Voorhees A.S., Beutner K.R., Ryan C., Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65 (1): 137—74.Nast A., Gisondi P., Ormerod A.D., Saiag P., Smith C., Spuls P.I., Arenberger P., Bachelez H., Barker J., Dauden E., de Jong E.M., Feist E., Jacobs A., Jobling R., Kemény L., Maccarone M., Mrowietz U., Papp K.A., Paul C., Reich K., Rosumeck S., Talme T., Thio H.B., van de Kerkhof P., Werner R.N., Yawalkar N. European S3-Guidelines on the systemic treatmen of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec; 29 (12): 2277—94.Псориаз. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс, 2016: 415—470. [Psoriasis. National Clinical Guidelines. Dermatovenerology 2015: Skin disease. Sexually transmitted infections. 5 edition Delovoy Express, 2016; 415—470 (Russia).]Natsis N.E., Gottlieb A.B. Bimekizumab for the treatment of psoriatic disease. Expert Opin Biol Ther. 2018 Dec; 18 (12): 1193—1197.Papp K.A., Merola J.F., Gottlieb A.B., Griffiths CEM, Cross N., Peterson L., Cioffi C., Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018 Aug; 79 (2): 277—286.Radtke M.A., Reich K., Spehr C., Augustin M. Treatment goals in psoriasis routine care. Arch Dermatol Res. 2015 Jul; 307 (5): 445—9.Nast A., Jacobs A., Rosumeck S., Werner R.N. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2015 Nov; 135 (11): 2641—2648.Thaçi D., Blauvelt A., Reich K., Tsai T.F., Vanaclocha F., Kingo K., Ziv M., Pinter A., Hugot S., You R., Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep; 73 (3): 400—9.Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2 (1):1. Epub 2012 Mar 17.Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part. 2. Dermatol Ther (Heidelb). 2012 Dec; 2 (1): 2. Epub 2012 Mar 30.Nast A. et al. Germany Guidelines S3-Leitlinie 013-001 „Therapie der Psoriasis vulgaris“, 2017.C. Smith et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 doi: 10.1111/bjd.15665Warren R.B. et al. J Invest Dermatol 2015; 135: 2632—40; Bewley et al. Poster PS-03 presented at 6th Annual Practical Symposium, 8—11 August 2019, Beawer Creek, Coloradо.Лила А.М., Мартынова Л.В. Генно-инженерные биологические препараты: проблема первичной и вторичной неэффективности. Вестник Санкт-Петербургской медицинской академии последипломного образования. 2011; 3 (4): 153—60. [A. Lila, L. Martynova. Biologics: primary and secondary non responders. Vestnik of Sankt-Peterburg Medical Academy postgraduate education. 2011; 3 (4): 153—60 (Russia).]Becher Strand et al/ Immunogenicity of biologics in chronic inflammatory diseases. A systematic review. BioDrugs 2017; 31 (4): 299—316.Инструкция по медицинскому применению препарата Тремфея. РУ ЛП-005686. [Sammary Product Characteristic of Tremfeya. RU LP-005686 (Russia).]Инструкция по медицинскому применению препарата Талс. РУ ЛП-005200. [Sammary Product Characteristic for Tals. RU LP-005200 (Russia).]Бакулев А.Л. Стратегия «лечение до достижения цели» при псориазе. Актуальные вопросы устойчивости к биологической терапии. Вестник дерматологии и венерологии. 2016; (5): 32—38. [A. Bukulev. Strategy of results-oriented treatment for patients with psoriasis. Relevant issues of biological therapy persistence. Vestnik dermatologii i venerologii. 2016; 5: 32—38 (Russia).]Bissonnette R., Luger T., Thaçi D., Toth D., Lacombe A., Xia S., Mazur R., Patekar M., Charef P., Milutinovic M., Leonardi C., Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE ExtensionStudy). J Eur Acad Dermatol Venereol. 2018 Sep; 32 (9): 1507—1514.Egeberg A., Iversen L., Gniadecki R., Hvid L., Dam T.N., Bryld L.E., Skov L. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis — nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol. 2017 Jul; 31 (7): 1183—1187.Sholom G., Cohen A.D., Feldhamer I., Comaneshter D., Freud T., Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologics medications. JEADV 2020: Jan 17. doi: 10.1111/jdv.16205. [Epub ahead of print]Augustin M., Thaci D., Eyerich K., Pinter A., Radtke M., Lauffer F., Mrowietz U., Gerdes S., Pariser D., Lebwohl M., Sieder C., Melzer N., Reich K. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol. 2019 Apr 10. doi: 10.1111/bjd.17991.Bilal J., Berlinberg A., Bhattacharjee S., Trost J., Riaz I.B., Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018 Sep; 29 (6): 569—578.Jabbar-Lopez Z.K., Yiu ZZN, Ward V., Exton L.S., Mohd Mustapa M.F., Samarasekera E., Burden A.D., Murphy R., Owen C.M., Parslew R., Venning V., Warren R.B., Smith C.H. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. J Invest Dermatol. 2017 Aug; 137 (8): 1646—1654.